Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kil...
June 07 2018 - 7:00AM
Based on recent findings on apabetalone’s potential role in human
immunodeficiency virus (“HIV-1”) eradication, Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) is seeking a partnership
with an existing stakeholder in the ongoing fight against
HIV-1. The most recent publication titled: “The BET
bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1
reservoir cells following viral reactivation,” in Nature’s Acta
Pharmacologica Sinica (2018) 0:1–13; demonstrated apabetalone’s
abilities to expose and reactivate latent HIV-1 reservoirs, induce
HIV-1 latent cell death, and reduce the side effects of standard of
care (cART combination antiretroviral therapy).
“Bromodomain and extra-terminal (BET) proteins play a role in
maintaining HIV-1 in latent cell reservoirs inaccessible to
anti-viral agents. The virus hiding within the cells is the primary
reason for treatment failure and the inability to fully eliminate
the virus from a patient. Treatment with the BD2 selective BET
inhibitor apabetalone results in the activation and release of the
virus from the cells, allowing it to be targeted for eradication by
concurrent anti-viral therapy,” stated Ewelina Kulikowski, Senior
Vice President of Research and Development.
“Apabetalone’s unique epigenetic mechanism of
action has once again been tied to another important grievous
disease for which there is no cure. In order to help expedite
development in this space, interested HIV/AIDS stakeholders such as
patient advocacy groups, government health bodies, major
phamaceutical companies, and/or non-government research
organization (NRO’s) are encouraged to contact Resverlogix to
further the research and development of apabetalone as a
therapeutic for HIV-1 eradication,” stated Donald McCaffrey,
President & CEO of Resverlogix.
Resverlogix continues the development of
apabetalone in high-risk CVD patients with type 2 diabetes mellitus
and low levels of high-density lipoprotein (HDL), as well as in
chronic kidney disease and Fabry disease. About HIV &
HIV Latency
According to the UNAIDS foundation there was an estimated 36.7
million people living with HIV globally in 2016, of which 20.9
million people were estimated to be accessing HIV antiretroviral
therapy by June 2017. The treatment for HIV is a lifelong process
requiring continuous medication. Reducing the frequency with which
medication needs to be taken would not only improve quality of life
and adherence to therapies, but also decrease the economic burden
associated with HIV treatment. Latent HIV-1 reservoirs are the main
cause of treatment failure. Latency reversal agents
(LRAs) which would deplete latent HIV
reservoirs, in conjunction with combination anti-retroviral
agents, would allow for effective killing and eradication of
HIV.
About
ResverlogixResverlogix is developing apabetalone
(RVX-208), a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is a BET inhibitor selective for
the second bromodomain (BD2) within the BET proteins. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease (CVD), diabetes
mellitus (DM), chronic kidney disease, end-stage renal disease
treated with hemodialysis, neurodegenerative disease, Fabry
disease, peripheral artery disease and other orphan diseases, while
maintaining a well described safety profile. Apabetalone is
currently being studied in a Phase 3 trial, BETonMACE, in high-risk
CVD patients with type 2 DM and low high-density lipoprotein (HDL).
In BETonMACE approximately 11% of the participants have chronic
kidney disease.
The Company’s kidney program is assessing
apabetalone’s effect in non-dialysis patients as well as in
patients on dialysis with the eventual objective of addressing the
huge medical need and demonstrate improved health outcomes.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations Email:ir@resverlogix.com Phone:
403-254-9252Or visit our website: www.resverlogix.com
This news release may contain certain
forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact,
including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should",
"expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward
looking information relating to, and the potential role of
apabetalone in the treatment of HIV-1, AIDS, CVD, DM, chronic
kidney disease, end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject
to numerous assumptions and risk factors including those discussed
in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Resverlogix (TSX:RVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Sep 2023 to Sep 2024